Vida Ventures Advisors LLC's Q2 2025 13F: 1 exit
Form 13F-HR for the quarter ended Jun 30, 2025 · filed Jul 10, 2025 · 2 reported positions · accession 0000950123-25-006247
What changed this quarter
| Activity | Security | Weight before | Weight now | Change | Shares | Shares % |
|---|---|---|---|---|---|---|
| Exited | Kronos Bio, Inc. (KRON) | 16.7% | — | −16.7 pts | −2.77M sh | −100% |
Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled
Top 10 positions — 100.0% of the equity book
Changes in the top 10 this quarter: KRON left
| # | Security | Weight before | Weight now | |
|---|---|---|---|---|
| 1 | Kyverna Therapeutics, Inc. (KYTX) | 64.0% | 87.2% | |
| 2 | Allogene Therapeutics, Inc. (ALLO) | 19.3% | 12.8% | |
| — | Kronos Bio, Inc. (KRON) | 16.7% | 0.0% | Left the top 10 |
Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).